Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2019 1
2021 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Pringsheim T, et al. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. Neurology. 2021. PMID: 34782410 Free PMC article. Review.
Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release levodopa for motor symptoms in early disease. ...
Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release levodopa for mo …
Twelve-month safety of entacapone in patients with Parkinson's disease.
Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Myllylä VV, et al. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. Eur J Neurol. 2001. PMID: 11509081 Clinical Trial.
As expected, due to dopaminergic enhancement, dyskinesia was more frequent as an AE with entacapone than with placebo. Dryness of mouth, urine discoloration and diarrhoea were more frequent non-dopaminergic AEs with entacapone than with placebo. ...Monitoring …
As expected, due to dopaminergic enhancement, dyskinesia was more frequent as an AE with entacapone than with placebo. Dryness …
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A; CAMP Study Group. Deuschl G, et al. Mov Disord. 2007 Aug 15;22(11):1550-5. doi: 10.1002/mds.21473. Mov Disord. 2007. PMID: 17516484 Clinical Trial.
A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious AE (dehydration) was recorded with each treatment group. ...The clinical benefit was more quickly apparent with ENT, which also showe …
A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious …
Safety of COMT-inhibitors in parkinson's disease: a phase-IV comparative study on adverse events of Tolcapone, Entacapone and Opicapone.
Pecoraro PM, Carbone SP, Bugamelli F, di Biase L. Pecoraro PM, et al. J Neural Transm (Vienna). 2025 Nov 1. doi: 10.1007/s00702-025-03053-4. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 41175235
Statistical comparisons were performed using Fisher's exact test to assess differences in AE rates. Entacapone was sold 100 times more than Opicapone and 1000 times more than Tolcapone. ...Tolcapone also exhibited a significantly lower AE risk than Opicapone …
Statistical comparisons were performed using Fisher's exact test to assess differences in AE rates. Entacapone was sold 100 ti …
Complications associated with intestinal infusion therapies in patients with Parkinson's disease: a single-center retrospective study and 15-year experience.
Straka I, Andre Z, Kosutzka Z, Gmitterova K, Stevove M, Durkovicova Z, Juricek R, Valkovic P, Minar M. Straka I, et al. Front Neurol. 2025 May 14;16:1547557. doi: 10.3389/fneur.2025.1547557. eCollection 2025. Front Neurol. 2025. PMID: 40438578 Free PMC article.
Advanced therapies, such as levodopa/carbidopa intestinal gel or carbidopa/levodopa enteral suspension (LCIG/CLES) and levodopa/entacapone/carbidopa intestinal gel (LECIG), offer continuous levodopa administration to reduce fluctuations and improve QoL. ...A total of 77.4% …
Advanced therapies, such as levodopa/carbidopa intestinal gel or carbidopa/levodopa enteral suspension (LCIG/CLES) and levodopa/entacapon …